| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement of reviewers 2014
|
|
|
2015
|
77 |
1 |
p. 217-220
|
artikel
|
| 2 |
A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer
|
AL-Tweigeri, Taher
|
|
2015
|
77 |
1 |
p. 147-153
|
artikel
|
| 3 |
A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells
|
Zhen, Ni
|
|
2015
|
77 |
1 |
p. 169-180
|
artikel
|
| 4 |
A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site
|
Shin, Dong-Yeop
|
|
2015
|
77 |
1 |
p. 163-168
|
artikel
|
| 5 |
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors
|
Schöffski, Patrick
|
|
2015
|
77 |
1 |
p. 99-108
|
artikel
|
| 6 |
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
|
Cereda, S.
|
|
2015
|
77 |
1 |
p. 109-114
|
artikel
|
| 7 |
Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)
|
Garcia del Muro, Xavier
|
|
2015
|
77 |
1 |
p. 133-146
|
artikel
|
| 8 |
Contemporary reviews on cancer treatment
|
Peters, Godefridus J.
|
|
2015
|
77 |
1 |
p. 3-4
|
artikel
|
| 9 |
Cytotoxic drugs: past, present and future
|
Newell, Herbie
|
|
2015
|
77 |
1 |
p. 1
|
artikel
|
| 10 |
Early metabolic change in 18F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients’ survival: PEACH study
|
Tanaka, Yusuke
|
|
2015
|
77 |
1 |
p. 121-126
|
artikel
|
| 11 |
Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer
|
Tas, Faruk
|
|
2015
|
77 |
1 |
p. 127-131
|
artikel
|
| 12 |
Enhanced brain distribution of carboplatin in a primate model after blood–brain barrier disruption using an implantable ultrasound device
|
Goldwirt, Lauriane
|
|
2015
|
77 |
1 |
p. 211-216
|
artikel
|
| 13 |
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
|
Owonikoko, Taofeek Kunle
|
|
2015
|
77 |
1 |
p. 155-162
|
artikel
|
| 14 |
High CYP2C19 phenotypic variability in gastrointestinal cancer patients
|
Burns, K. E.
|
|
2015
|
77 |
1 |
p. 195-204
|
artikel
|
| 15 |
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
|
Mazza, Elena
|
|
2015
|
77 |
1 |
p. 115-120
|
artikel
|
| 16 |
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis
|
Arbitrio, Mariamena
|
|
2015
|
77 |
1 |
p. 205-209
|
artikel
|
| 17 |
Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice
|
Attia, S. M.
|
|
2015
|
77 |
1 |
p. 27-33
|
artikel
|
| 18 |
Malformin A1 promotes cell death through induction of apoptosis, necrosis and autophagy in prostate cancer cells
|
Liu, Yongqing
|
|
2015
|
77 |
1 |
p. 63-75
|
artikel
|
| 19 |
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human
|
Waters, Nigel J.
|
|
2015
|
77 |
1 |
p. 43-62
|
artikel
|
| 20 |
Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy
|
Perego, Paola
|
|
2015
|
77 |
1 |
p. 5-18
|
artikel
|
| 21 |
Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells
|
Miao, Xin
|
|
2015
|
77 |
1 |
p. 181-193
|
artikel
|
| 22 |
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma
|
Yanagimoto, Hiroaki
|
|
2015
|
77 |
1 |
p. 35-41
|
artikel
|
| 23 |
Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
|
Quartino, Angelica L.
|
|
2015
|
77 |
1 |
p. 77-88
|
artikel
|
| 24 |
Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies
|
Jin, Feng
|
|
2015
|
77 |
1 |
p. 89-98
|
artikel
|
| 25 |
The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
|
Ruggiero, Antonio
|
|
2015
|
77 |
1 |
p. 19-26
|
artikel
|
Tijdschrift beschrijving